Col­orec­tal drug can­di­dates fo­cal point of new col­lab­o­ra­tion be­tween Servi­er, Cel­sius Ther­a­peu­tics

A well-known in­ter­na­tion­al phar­ma­ceu­ti­cal com­pa­ny and a rel­a­tive­ly new US pre­ci­sion ther­a­peu­tics start­up are join­ing forces to iden­ti­fy and val­i­date nov­el col­orec­tal can­cer drug tar­gets.

French phar­ma Servi­er and Cam­bridge, MA-based start­up Cel­sius Ther­a­peu­tics will work to­geth­er over a three-year pe­ri­od to re­search, de­vel­op, and com­mer­cial­ize up to three of the most promis­ing col­orec­tal can­cer drug dis­cov­ery tar­gets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER